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b-Lactamases are the main cause of bacterial resistance to
penicillins, cephalosporins and related b-lactam compounds.
These enzymes inactivate the antibiotics by hydrolysing the
amide bond of the b-lactam ring. Class A b-lactamases are the
most widespread enzymes and are responsible for numerous
failures in the treatment of infectious diseases. The introduction
of new b-lactam compounds, which are meant to be ‘b-lactamase-
stable ’ or b-lactamase inhibitors, is thus continuously challenged
either by point mutations in the ubiquitous TEM and SHV
plasmid-borne b-lactamase genes or by the acquisition of new
genes coding for b-lactamases with different catalytic properties.
1. INTRODUCTION
The introduction of benzylpenicillin in clinical trials about 50
years ago clearly represents one of the major breakthroughs in
modern chemotherapy. The success of penicillins and related
compounds (b-lactam antibiotics or b-lactams), which are cur-
rently the most widely used antibacterial agents, rests on both
their high efficiency and their specificity [1]. However, as soon as
b-lactams were introduced as chemotherapeutic weapons, this
efficiency was challenged by the emergence of resistant pathogenic
strains. In consequence, new molecules have been progressively
introduced, with structures increasingly different from those of
the original drugs. Thus the b-lactam antibiotics form an ever-
expanding family of compounds, whose only common feature is
the four-membered b-lactam ring (Figure 1).
The b-lactam antibiotics interfere in a specific way with the
biosynthesis of the peptidoglycan [1–3]. This major constituent
of the bacterial cell wall forms a three-dimensional network
which completely surrounds the bacterium and protects it from
its own osmotic pressure [4]. The peptidoglycan is also an
essential element in maintaining the shape and rigidity of the cell
wall, in both Gram-positive and Gram-negative bacteria. This
macromolecule is unique to the bacterial world, which explains
the high specificity of antibiotics interfering with its biosynthesis.
2. TARGET ENZYMES: THE BACTERIAL DD-PEPTIDASES
The physiological targets of b-lactam compounds are membrane
DD-peptidases [often called penicillin-binding proteins (PBPs)],
which are responsible for the synthesis and remodelling of the
peptidoglycan [1,2,5]. These lethal targets in bacteria are active-
site serine enzymes which perform their catalytic cycle according
to an acylation}deacylation mechanism, involving transient acyl-
enzyme adducts [4,6]. Similarly, b-lactam antibiotics acylate the
active-site serine residue of the DD-peptidases, forming rather
stable covalent non-catalytic acyl-enzymes. This results in the
formation of non-functional peptidoglycan and, eventually, in
Abbreviations used: PBP, penicillin-binding protein ; MIC, minimum inhibitory concentration ; ES, extended spectrum; IRT, inhibitor-resistant TEM
b-lactamase.
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On the basis of the X-ray crystallography structures of several
class A b-lactamases, including that of the clinically relevant
TEM-1 enzyme, it has become possible to analyse how particular
structural changes in the enzyme structures might modify their
catalytic properties. However, despite the many available kinetic,
structural and mutagenesis data, the factors explaining the
diversity of the specificity profiles of class A b-lactamases and
their amazing catalytic efficiency have not been thoroughly
elucidated. The detailed understanding of these phenomena
constitutes the cornerstone for the design of future generations of
antibiotics.
cell death [4]. This mechanism is schematically represented by a











where E is the enzyme, C the antibiotic, EC a non-covalent
Henri–Michaelis complex, EC* a covalent acyl-enzyme and P(s)
the inactive degradation product(s) of the antibiotic (see Figure
2).
The two complexes EC and EC* are enzymically inactive and
the antibiotic efficiency rests on both a high k
#
}K« value (generally
due to a high k
#
value) and a very low k
$
value, which results in
acyl-enzyme (EC*) accumulation at the steady-state. The co-
valent complex EC* results from the nucleophilic attack of the
carbonyl carbon atom of the b-lactam ring by the hydroxyl
group of the side-chain of the essential active-site serine. This
model applies to all DD-peptidases [1] and the same serine
residue is also critical for the interaction of these enzymes with
their physiological substrates (d-alanyl-d-alanine-terminated
peptides ; [7–9]). It seems that the enzyme forms a similar acyl-
enzyme adduct with its peptide substrates, but the k
$
value is
much higher than with penicillins. The b-lactam antibiotics,
which are recognized as natural substrates by the PBPs, are thus
mechanism-based inactivators or suicide substrates of the DD-
peptidases}PBPs.
3. b-LACTAMASES
Asmentioned above, resistance phenomena have recently become
increasingly widespread and worrying (see [10,11], and related
papers in the same issues). Besides DD-peptidases of increased
resistance, and the modification of the permeability barrier
[3,12,13], the synthesis of one or several b-lactamases represents
the most widespread and often the most efficient mechanism
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Figure 1 Structure of some b-lactam antibiotics
(A) Penams (e.g. benzylpenicillin, ampicillin, amoxycillin), (B) cephems (cephalosporins), (C)
cephamycins (e.g. cefoxitin), (D) cefotaxime (oximino cephalosporin ; R¯ CH2EOECOECH3),
(E) oxacephamycins (e.g. moxalactam), (F) carbapenems (e.g. imipenem), (G) clavulanate
(oxapenam), (H) monobactams (e.g. aztreonam), (I) temocillin (6-a-methoxy penam) and (J)
sulbactam (penam sulphone).
devised by bacteria to escape the lethal action of b-lactam
antibiotics [10,14–16].
b-Lactamases catalyse very efficiently the irreversible hydro-
lysis of the amide bond of the b-lactam ring, thus yielding
biologically inactive product(s) ([14,17] ; Figure 2). Today, it
clearly appears that the therapeutic future of the b-lactam
antibiotics is seriously challenged and that a solution to the
problem of bacterial resistance due to b-lactamase production is
urgently needed. This demanding task is further complicated by
the ‘genetic fluidity ’ of microbial populations, which allows a
widespread and frightening dissemination of resistance genes
[10,16,18,19], and by the occurrence of single-point mutations in
these b-lactamase-coding genes, resulting in the production of an
ever-expanding number of enzymes with new substrate profiles
[20–23]. b-Lactamases, which can be chromosome or plasmid
encoded and produced in a constitutive or inducible manner, are
secreted into the periplasmic space of Gram-negative strains or
into the outer medium by their Gram-positive counterparts.
Membrane-associated enzymes have also been reported, but only
in a few instances (Bacillus licheniformis and Bacillus cereus [24] ;
Bacteroides ulgatus [25]).
The main division of b-lactamases is based on the chemistry of
their catalytic mechanisms, and distinguishes serine and zinc
enzymes [17]. Most b-lactamases display an active-site serine
residue and function by the three-step mechanism described
Figure 2 General catalytic pathway of active-site serine b-lactamases
In general, both acylation (k2) and hydrolysis of the acyl-enzyme (k3) are rapid, resulting in high
turnover numbers [kcat ¯ k2¬k3/(k2­k3)] and specificity constants [kcat/Km ¯ k2/K« where
K«¯ (k
−1
­k2)/k+1)]. Note that the kcat/Km parameter (also sometimes misleadingly referred
to as the ‘ catalytic efficiency ’) corresponds to the apparent second-order rate constant for acyl-
enzyme formation (k2/K«), and thus is independent of the deacylation rate. Hence the genuine
catalytic efficiency of the enzyme rests on high values of both kcat/Km and kcat.
above for the DD-peptidases, involving the transient formation
of an acyl-enzyme (model 1 and Figure 2) in which the hy-
droxyl group of the essential serine residue is esterified by
the carbonyl group of the antibiotic moiety [13,17,26]. On the
basis of their amino acid sequences, these active-site serine b-
lactamases are divided into three molecular classes A, C and D
[27–30]. A minority of enzymes aremetalloproteinswhose activity
relies on the presence of one or two Zn#+ ion(s) in their active site
and appears to involve only non-covalent intermediates [17,31].
For historical reasons, they are known as class B b-lactamases.
All these Zn#+-dependent enzymes significantly hydrolyse carba-
penems (Figure 1F; section 9.2) and, in some cases, the classical
inactivators of the more prevalent class A b-lactamases. Although
they represent a new clinical problem [32,33], Zn#+-enzymes are
still vastly outnumbered by the active-site serine b-lactamases
which represent a more immediate threat.
4. ACTIVE SITE SERINE b-LACTAMASES
Interestingly, according to model 1 (and Figure 2), the b-lactam
compounds appear to form a similar adduct when reacting with
their physiological targets (the DD-peptidases) and with active-
site serine b-lactamases. The difference between these two types
of enzymes is purely quantitative. Indeed, with the former, the k
$
values are very low (hardly ever above 0±001 s−" ; [1]) and the
acyl-enzymes are very stable (t
"/#
" 10 min), whereas with the
latter very high k
$
values are observed [up to C 10000 s−" for the
interaction between the B. licheniformis and the Streptomyces
albus G b-lactamases and benzylpenicillin at 30 °C (A. Matagne,
S. G. Waley and J.-M. Fre' re, unpublished work). Also the rate





, see Figure 2) is generally larger with b-
lactamases, sometimes close to the diffusion-limited values of
10(–10) M−"[s−". These purely quantitative differences result in
sharp qualitative differences, as b-lactamases inactivate peni-
cillins, whereas penicillins inactivate PBPs [1].
5. X-RAY CRYSTALLOGRAPHIC DATA
The similarity between b-lactamases and DD-peptidases is not
restricted to ‘mechanistic ’ properties. Indeed, X-ray diffraction
studies have highlighted striking structural analogies between the
Streptomyces R61 (S. R61) DD-peptidase and several class A




































Figure 3 Comparison of the tertiary structures of the S. R61 DD-peptidase (A), the E. cloacae class C b-lactamase (B) and the class A TEM
b-lactamase (C)
The a-carbon of the active-site serine is marked by a star and those of the residues discussed in the text by a dot. These diagrams were generated using MOLSCRIPT [38].
medium-sized monomeric proteins (M
r
values of about 29000
and 39000 for class A and class C b-lactamases respectively, and
37500 for the S. R61 DD-peptidase), which are made up of two
structural domains (an all-a and an a}b domain) with the active
site situated in a groove between the two domains (Figure 3).
Compared with the class A b-lactamases, the class C enzymes
and the S. R61 PBP have additional loops and secondary
structures on the surface of the all-a domain, at a distance from
the active site. The active serine is situated at the N-terminus of
the rather long, hydrophobic first helix of the all-a domain (a-2
helix). Interestingly, the first three-dimensional crystal structure
of a high-molecular-mass PBP [6] has recently been reported at
3±5 AI resolution [39]. This large molecule (M
r
value C 80000)












Figure 4 Residues and hydrogen bond network (dotted lines) in the active
site of the TEM b-lactamase
The side chains of residues thought to take part in the catalytic process are coloured red and
identified. The two conserved water molecules which are hypothesized to take part in the
catalytic process are also shown (W1 and W2).
has three domains, the central one being responsible for the
transpeptidase activity and for penicillin binding. This trans-
peptidase domain also shows marked similarities to the active-
site serine b-lactamases. These new structural data supply further
evidence supporting the existence of a close relationship between
these two families of penicillin-recognizing enzymes
[2,34,35,37,40] and support the hypothesis of a common ancestor
protein for DD-peptidases and b-lactamases [41]. This super-
family of active-site serine penicillin-recognizing enzymes [42]
would thus be the perfect illustration of a divergent evolution
from a common precursor, analogous to the case of pancreatic
serine proteases (trypsin, chymotrypsin and elastase), of carboxy-
peptidases A and B, and of hen egg white and bacteriophage T4
lysozymes [43,44].
In the immediate vicinity of the active-site serine residue of
DD-peptidases and b-lactamases (Figure 3), several conserved
elements have been identified which appear to be directly or
indirectly involved in the substrate recognition and catalytic
processes. Careful comparisons of the primary and tertiary
structures have allowed identification of the same structural and
functional elements in all active-site serine penicillin-recognizing
enzymes [2,30,42,45].
The first element contains the active serine and, one helix-turn
downstream, a lysine residue whose side-chain also points into
the active site (Ser-Xaa-Xaa-Lys sequence). The proximity of the
serine and lysine side-chains, which are hydrogen-bonded (Figure
4), suggested the likely involvement of the lysine side-chain
amino group in the catalytic process [46–48].
The second element is situated on a short loop in the all-a
domain, where it forms one side of the catalytic cavity. It consists
of Tyr-Xaa-Asn (b-lactamases of classes C and D, some PBPs) or
Ser-Xaa-Asn (b-lactamases of class A, most PBPs) sequences.
The side-chains of the first and third residues point into the
active-site cleft, while that of the second residue lies in the protein
core. The first residue (Ser or Tyr) is hydroxylated, and the third
is nearly always an asparagine. In class A b-lactamases, the
Ser"$!-Asp"$"-Asn"$# motif (also called the SDN loop) is nearly
invariant, the only exceptions being the Asn"$#!Ser and the
Asn"$#!Gly substitutions in the B. cereus III and Myco-
bacterium tuberculosis b-lactamases respectively (Table 1).
The third element is on the innermost strand of the b-sheet
(a}b domain) and forms the opposite wall of the catalytic cavity.
It is generally a Lys-Thr-Gly sequence, but Lys is replaced by His
or Arg in a few exceptional cases and Thr by Ser in several class
A b-lactamases (position 235 in Figure 3C). A positive side-
chain, followed by one bearing a hydroxyl group, appears to be
universally conserved. The third member of this so-called KTG
triad is devoid of side-chains and is strictly conserved in the
superfamily of active-site serine penicillin-recognizing enzymes
[42]. Actually any side-chain at this position would severely
impair the approach of the substrate. The side chain of the Lys
residue forms a hydrogen-bond with the hydroxyl group of the
Ser}Tyr residue of the second element (Figure 4).
A fourth element, containing a negatively charged residue, has
been tentatively identified in all enzymes, but it seems to play a
catalytic role only in class A b-lactamases, where it is situated on
a 16–19 residues loop (Arg"'"-Asn"(* in TEM-1 [49]) usually
referred to as the X-loop. In most cases, this loop contains the
Glu"''-Xaa-Glu-Leu-Asn"(! sequence where the two residues
Glu-166 and Asn-170 seem essential in positioning the conserved
water molecule W1 very close to the active serine [50].
X-ray data, where available, indicate that most of these
conserved residues in the superfamily of penicillin-recognizing
enzymes are intimately involved in a dense, structurally conserved
hydrogen-bonding network within the active-site cavity (Figure
4).
Of all these enzymes, class A b-lactamases are the most
numerous and the most widely studied. A very high number of
enzymes have been reported and more than 45 sequences
determined (not considering the numerous variants in the
TEM and SHV families ; see section 7). The three-dimensional
structures of six class A enzymes are known, most of them at
high resolution ²B. cereus I [35] ; S. albus G [50,51] ; Staphyl-
ococcus aureus PC1 [46,52] ; B. licheniformis 749}C [47,53] ;
TEM-1 [48,49,54,55] ; NMC-A (P. Swaren, J.-M. Fre' re and J. P.
Samama, unpublished work)´, and the function of numerous
residues has been probed by site-directed mutagenesis. Never-
theless, their catalytic mechanism remains controversial and it
proves particularly hazardous to establish correlations between
the sequence data and the highly variable substrate profiles [56].
This review focuses on the properties of class A b-lactamases.
Many studies have been performed involving the modification of
the conserved residues described above, and has been extensively
reviewed by us [57]. Here we discuss the most recent findings
arising from the analysis of both newly discovered enzymes
and newly designed mutants. Throughout this discussion, the
consensus numbering scheme proposed by Ambler et al. [58] will
be used to facilitate comparisons between these homologous
proteins (ABL scheme).
6. CATALYTIC MECHANISM
By analogy with the widely studied mechanism of serine proteases
[44,59], which also hydrolyse amide bonds and involve an acyl-
enzyme intermediate, the active site of b-lactamases would be
expected to contain a specific amino acid side-chain which
increases the nucleophilicity of the hydroxyl of Ser-70 by acting
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Table 1 Conserved residues in all class A b-lactamases
Amino acid at position
β-Lactamase 37 45 66 70 73 81 107 130 131 132 134 136 144 156







B. uniformis (cblA) Leu Asp Ser
B. fragilis (cepA) Ile Tyr Ala Asp
B. vulgatus (cfxA)‡ Val Tyr Cys Asn Pro
Sme-1/NmcA/IMI-1
Amino acid at position
β-Lactamase 157 164 166 169 179 180 199 207 233 234 235 236 References
ABL consensus* Asp Arg Glu Leu Asp Thr Leu Leu Asp Lys/ Thr/ Gly [58,140,158,165,176–178]
(Arg) (Ser)




Per-1/Per-2† Ile/Val Ala Met Asn Trp His [151,161]
B. uniformis Ile Glu Met Asn Trp Phe His [160]
B. fragilis Ile His Met Asn Trp Phe Ile His [160]
B. vulgatus (cfxA)‡ Arg Tyr Met Asn Tyr Ile Ile His [160,161]
Sme-1/NmcA/IMI-1 Tyr [169,171]
Residues involved in the catalytic mechanism and/or in substrate binding are shown in bold type. Columns corresponding to strictly conserved residues are shaded in grey.
* K.  pneumoniae LEN-1; SHV-1; TEM-1; P. aeruginosa PSE-3; PSE-4 ; R. capsulata ; A. R39 ; B. cereus 569/H type I ; B. cereus 5/B type I ; B. cereus 569/H type III ; B. licheniformis ; S. badius ; S.
cacaoi blaU; S. cacaoi Ulg ; K. oxytoca E23004; S. aureus PC1 ; S. aureofaciens ; S. albus G ; S. lavendulae ; S. fradiae ; H. influenzae ROB-1; CARB-4 ; S. cellulosae ; C. diversus ; Y. enterocolitica ; B. mycoides ;
E. faecalis ; K. oxytoca D488; E. coli MEN-1 (CTX-M-1); P. mirabilis GN 79 ; M. fortuitum ; E. coli Toho-1; CTX-M-2 ; S. fonticola. Among these 34 sequences, a Ser is found at position 132 only in B. cereus
III. Three carbenicillin-hydrolysing enzymes (PSE-4 [181], CARB-4 [182] and P. mirabilis GN 79 [183]) display an Arg at position 234 (note that a similar K234R substitution also occurs in PSE-1 [184]
and CARB-3 [185]). A hydroxylated residue, either Ser (in 13 sequences) or Thr (in 21 sequences), is invariably found at position 235.
† Per-1 and Per-2 display 86.4% isology. An Ile residue and a Val residue are found in position 157 in Per-1 and Per-2 respectively.
‡ Due to a different alignment, Nordmann and Naas [161] found an Ile and a Pro at positions 156 and 157 respectively.
as a general base catalyst. In most serine proteases, this function
has long been known to be fulfilled by the imidazole group of a
histidine residue. In contrast, the mechanism of proton ab-
straction and donation during hydrolysis of b-lactam compounds
by the active-site serine b-lactamases is still the subject of
considerable discussion.
The most controversial situation prevails for class A enzymes,
for which two distinct residues have been proposed for the role
of general base. In one hypothesis [50,60–62], this role is played
by the conservedGlu-166. Crystallographic data have highlighted
the presence of a tightly bound water molecule, forming a bridge
between the Ser-70 hydroxyl group and the Glu-166 carboxylate
side chain. This water molecule (W1) is found in the same
position in all the high-resolution class A structures [47,49,
50,52]. Although site-directed mutagenesis experiments suggested
that Glu-166 might play the role of general base in the
acylation reaction [60], it seems too far away from the Ser-70 OH
group to do so directly. Molecular modelling studies [50] have
suggested that the conserved water molecule might act as a relay
molecule in the transfer of the proton between the Ser-70 and
Glu-166 side chains. Alternatively, the flexibility of the X-loop
might allow the distance between the two residues to be shortened
during the acylation process [63]. In both cases, the activated c-
O of Ser-70 can then attack the b-lactam carbonyl carbon on the
well-exposed a-face of the molecule, and the abstracted proton is
back-donated to the nitrogen atom of the b-lactam through the
hydrogen-bonding sub-network (Figure 4) involving a second
water molecule (W2), the e-amino groups of Lys-73 and Lys-234
and the hydroxyl group of Ser-130, which acts as the last proton
donor [50,61] (note the different proposal by Mobashery and co-
workers [64,65], who suggested that Ser-130 lowers the energy
barrier for hydrolysis of substrates by merely hydrogen-bonding
to the nitrogen atom of the b-lactam ring in the course of Ser-70
acylation). Hydrolysis of this serine-ester-linked penicilloyl-
enzyme would subsequently occur according to a symmetrical
mechanism, where Glu-166 would activate theW1water molecule
to attack the carbonyl carbon of the acyl-enzyme and ensure
back-delivery of the abstracted proton to the Ser-70 c-O atom,
ultimately leading to enzyme regeneration [50]. The role of Glu-
166 (proton abstractor) in the deacylation step, originally sug-
gested by Herzberg and Moult [46] on the basis of the refined
structure of the S. aureus PC1 b-lactamase, has been widely
accepted.
During both acylation and deacylation, elusive tetrahedral
transition-state intermediates are formed in which the b-lactam
carbonyl oxygen is negatively charged. This charge is stabilized
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Table 2 Comparison of the kcat/Km values (mM−
1[s−1) for the interaction of some characteristic b-lactams with carbapenem-hydrolysing b-lactamases and
various enzymes of class A
Values in parentheses are relative to those for benzylpenicillin arbitrarily fixed at 100. The data are from (1) Mariotte-Boyer et al. [175] ; (2) P. Sware! n, J.-M. Fre' re and J. P. Samama, unpublished
work ; (3) Raquet et al. [132] ; (4) Rasmussen et al. [171] ; (5) Raquet et al. [99] ; (6) Fisher et al. [26] ; (7) Miyashita et al. [173] ; (8) Matagne et al. [56,72,83]. (*) poor inactivator with Ki C 2 mM
[186]. ND, not determined.
NmcA(1,2) Sme-1(3) IMI-1(4) TEM-1(3,5–7) S. albus G(8) A. R39(8)
Benzylpenicillin 9300 (100) 1400 (100) 560 (100) 84000 (100) 2800 (100) 7500 (100)
Ampicillin ND 730 (52) 240 (44) 33000 (39) 6100 (220) 16000 (210)
Ticarcillin 530 (6) 130 (9) ND ND 125 (4±5) 800 (11)
Penicillanate ND ND ND 66 (0±08) 61 (2±2) 590 (8)
6-a-(Hydroxymethyl)-
penicillanate
100 (1) ND ND 1±2 (0±0015) ND ND
Cephaloridine ND 1530 (110) 1900 (340) 2200 (2±6) 620 (22) 11600 (150)
Cephalothin 15200 (160) 1620 (120) 920 (160) 650 (0±8) 370 (13) 3700 (49)
Nitrocefin ND 6150 (440) 3500 (630) 17000 (20) 2400 (86) 8500 (73)
Cefotaxime 300 (3) ND 18 (3) 1±5 (0±002) 1 (0±04) 400 (5)
Ceftazidime 52 (0±6) ND 0±024 (0±004) 0±07 (8¬10−5) ! 0±001 13 (0±2)
Cefoxitin 62 (0±7) 2±2 (0±2) 6±7 (1±2) 0±006 (7¬10−6) ! 3¬10−5 0±002 (2¬10−5)
Moxalactam 29 (0±3) ND ND (*) ! 3¬10−5 0±0003 (5¬10−6)
Aztreonam 5600 (60) ND 550 (98) 0±7 (8¬10−4) 0±4 (0±01) 76 (1)
Imipenem 11300 (120) 1620 (120) 520 (93) 1±5–2±5 (C 0±002) 0±32 (0±01) 9 (0±12)
Meropenem 2750 (30) ND 380 (69) ND ND ND
by hydrogen-bonding interactions with the backbone NH groups
of Ser-70 and residue 237, which thus form an ‘oxyanion hole’
reminiscent of that found in serine proteases [46,48,50,66,67].
The second hypothesis [48,68,69] mainly rests on the structural
properties of the Glu-166!Asn mutant of the TEM-1 b-
lactamase [48], which forms long-lived acyl-enzymes [70]. The
authors argued that Glu-166 is expendable for acylation and thus
proposed an unsymmetrical mechanism, with two different
general bases, Lys-73 and Glu-166, participating in acylation and
deacylation respectively. Thus the e-amino group of a lysine side-
chain would act as the proton abstractor to increase the
nucleophilicity of the active-site serine, a mechanism which has
now been proposed for several proteases that contain an essential
lysine, but no essential histidine [59]. In this mechanism, the
enzyme must provide a favourable local environment to enable
the lysine to remain deprotonated at neutral pH. The strongly
reduced pK
a
value (C 5–6 pH units) for the alkylammonium
group of Lys-73 in class A b-lactamases would result both from
hydrogen-bonds with Ser-70, Asn-132 and the backbone carbonyl
of Ser-130 (Figure 4), and from a very positive electric field
created by the a-2 helix dipole, the alkylammonium group of
Lys-234 and, possibly, some other basic residues, such as Arg-
244 and Arg-164, located near the enzyme active site [48].
However, in the wild-type enzyme, the carboxylate group of
Glu-166 is much closer to the e-amino group of Lys-73 than is
any positively charged side-chain [49], and thus the active-site
negative charge of Glu-166 would be expected to hinder the
catalytic efficiency of the acylation process. Hence, removal of
this proximal negatively charged residue should actually increase
the rate of the acylation process. However, in all class A b-
lactamase mutants where Glu-166 was replaced by a neutral
residue (Ala, Cys, Tyr or Asn), the acylation step was found to
be significantly impeded.
Several Glu-166 mutants were prepared with various class A
enzymes, and whenever detailed kinetic studies were performed,
both acylation and deacylation rates appeared to be decreased by
the mutation, deacylation being sometimes more affected than
acylation (for a detailed review of these data, see [57]). Moreover,
as reported for the B. cereus 569}H b-lactamase I [60], the K73R
mutation causes a C 100-fold decrease in the value of k
#
for
benzylpenicillin hydrolysis, while its Glu-166!Asp counterpart





observation which seems to indicate a more important role for
Glu-166 than for Lys-73 in the acylation step. Most recently,
careful re-examination of the catalytic properties of the Glu-166
!Asn mutant of the TEM-1 b-lactamase [71] unambiguously
indicated that, if the mutation truly causes conversion of the
penicillin-hydrolysing TEM-1 b-lactamase into a PBP (due to an
extremely large decrease in the k
$
value, i.e. C 10*-fold for
benzylpenicillin), the k
#
}K« value, which characterizes the ef-
ficiency of acylation, was also significantly impaired (C 10$-fold
for benzylpenicillin). All these kinetic data seem to weaken the
hypothesis of an unsymmetrical mechanism [48] and are most
consistent with the mechanism proposed by Lamotte-Brasseur et
al. [50], where both acylation and deacylation involve Glu-166
acting as a general base via a conserved water molecule.
This latter hypothesis is further strengthened by kinetic and
modelling studies of b-lactam compounds bearing a methoxy
side-chain on the a-face of the b-lactam ring [72]. These molecules
(cefoxitin, moxalactam and temocillin ; Figure 1) acylate the
active serine of most class A enzymes with an exceedingly poor
efficiency (Table 2), and whenever acylation occurs, deacylation
proves to be even slower, both several orders of magnitude below
the rates observed with good substrates. Nevertheless, these
molecules easily fit into the active site [72], in a way very similar
to that observed with the best substrates, but the bulky methoxy
substituent displaces the water molecule W1, thus making both
acylation and deacylation very unlikely, as expected from the
symmetrical mechanism involving Glu-166. Conversely, the three
substrates considered in this study do not perturb the hydrogen-
bond between Ser-70 and Lys-73 and thus they should readily
acylate the enzyme if the second hypothesis were valid. Ad-
ditionally, and quite notably, the acylation rates by these very
bad substrates were found to be significantly facilitated in the
Glu-166!Asn mutant of TEM-1 [71]. These data suggested
that the acylation of the mutant might rely on an alternative
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mechanism, where the Lys-73 side chain would effectively replace
Glu-166 as the general base, as suggested by Strynadka et al. [48]
for the wild-type b-lactamase. In the mutant, removal of the
negative charge might explain the large decrease in the Lys-73
pK
a
value when compared with the wild-type enzyme. This
alternative mechanism may explain why in many Glu-166!Xaa
mutants, the acylation step was found to be less affected than the
deacylation step.
Finally, the pH dependence of the chemical modification of e-
amino groups and the NMR titration of the "$C-labelled lysine
residues in the TEM-1 b-lactamase [73] clearly indicated that the
pK
a
value (& 10) of the Lys-73 side-chain is not significantly
decreased in the wild-type enzyme, making it a very unlikely
candidate for proton abstraction in catalysis. Note also that a
crystallographic study of the Lys-73!His mutant of the S.
aureus PC1 b-lactamase, whose catalytic properties are severely
impaired, was recently reported [74]. The X-ray data indicated
that the imidazole ring is positively charged and that the only
significant deviation in side-chain conformation is that of the
catalytic serine residue, which adopts an alternative conformation
incompatible with nucleophilic attack on substrates. These
observations suggest that the positively charged alkylammonium
group of Lys-73 helps in orientating the Ser-70 hydroxyl group
for efficient catalysis.
Thus, although it can still be argued that a substantially
lowered pK
a
value prevails for Lys-73 when the substrate is
bound to the active site [67,74,75] (see also the mechanism
proposed by Sware!n et al. [76] who argue for a substantial
upward shift in the pK
a
of the unprotonated Lys-73 upon
substrate binding), most presently available data are inconsistent
with the second hypothesis (see [77,78] for further comments),
and seem to indicate that Glu-166 is the genuine general base
catalyst in both formation and hydrolysis of the acyl-enzyme
intermediate.
7. EXTENDED-SPECTRUM b-LACTAMASES OF THE TEM AND
SHV FAMILIES
In the struggle against b-lactamase-producing pathogenic bac-
teria, one strategy has been to search for, and use, b-lactam
compounds that are resistant to the hydrolytic action of these
enzymes, while retaining antibacterial activity [12,79]. Several
families of so-called ‘b-lactamase-stable ’ antibiotics are now
available. Third-generation cephalosporins (e.g. cefotaxime and
ceftazidime), which differ from first- and second-generation





in Figure 1B), and hence in their increased spectrum of
activity and potency [80,81], represent one such group, besides
cephamycins (cefoxitin), oxacephamycins (moxalactam), 6-a-
methyoxypenams (temocillin), monobactams (aztreonam) and
carbapenems (imipenem) (Figure 1). Their stability is neither
absolute nor general [56,82–84] and most of them behave as
sluggish substrates of the chromosome-encoded class C and
plasmid-borne SHV-1 and TEM-1 enzymes, but nevertheless
display fair to high efficiency against strains producing these b-
lactamases. In the past 15 years, the extensive and sometimes
abusive clinical utilization of these drugs has been responsible for
the appearance of an increasing number of resistant strains [3]. In
most cases, this could be attributed to the production of new
extended-spectrum (ES) b-lactamases [20–22,85]. These plasmid-
mediated enzymes confer resistance to ‘b-lactamase-stable ’ com-
pounds such as cefotaxime, ceftazidime and aztreonam, all
characterized by b-acyl side-chains containing an oximino group
(Figure 1). The large majority of these new enzymes belong to the
SHV and TEM families [86], the parent enzymes, TEM-1}2 (see
Table 3 Extended-spectrum b-lactamases of the SHV family
The data are compiled from previously published reports [21,92,107,187], where all references
can be found. Note that residues 238 and 240 are adjacent in both the SHV and TEM
sequences, an insertion occurring at this level in some homologous class A enzymes.
Amino acid at position
35 179 205 238 240 No. of mutations*
SHV-1 Leu Asp Arg Gly Glu —
SHV-2 Ser 1
SHV-2a Gly Ser 2
SHV-3 Leu Ser 2
SHV-4 Leu Ser Lys 3
SHV-5 Ser Lys 2
SHV-7 Ser Lys 3
SHV-8 Asn 1
SHV-11 Gln 1
SHV-12 Gln Ser 2
* Number of point mutations when compared with the parental type SHV-1.
 The same mutations occur in SHV-9. However, one deletion (Gly-45) and three
substitutions (Arg-140! Ala, Asn-192! Lys and Val-193! Leu) differentiate SHV-9 from
SHV-5, which are nevertheless functionally indistinguishable [156].
 An additional mutation occurs at position 43, where the highly conserved Arg is replaced
by Ser [187]. The role of that new substitution might be structural, although this is not clear
[110].
below) and SHV-1, sharing very similar primary structures [87]
and biochemical properties. To date, at least 29 TEM- and 11
SHV-related enzymes exhibiting increased hydrolytic activities
against the oximino b-lactams have been described [23,88–90].
Each variant enzyme has from one to four amino acid
substitutions when compared with the parental enzymes (Tables
3 and 4), and those mutations responsible for the new activity
profiles are restricted to Glu-104 (TEM), Arg-164 (TEM), Asp-
179 (SHV), Arg-205 (SHV), Ala-237 (TEM), Gly-238 and Glu-
240 (in both TEM and SHV), with the recent addition of Val-42
in the TEM-42 variant [91] and by Leu-35 in several SHV
derivatives [92]. In the TEM family, all the variants arise from
point mutations in the gene encoding either TEM-1 or TEM-2.
The Gln-39!Lys (TEM-2) and Thr-265!Met (TEM-13) muta-
tions, at positions quite distant from the active site (Figure 3C),
do not result in significant differences in the catalytic properties
[21,93–95], and thus TEM-1, TEM-2 and TEM-13 correspond to
parental phenotypes.
Not surprisingly, most residues involved in the extended-
spectrum properties of these enzymes were found to be located in
close proximity to the active-site cavity (Figure 3C). None of the
modified side-chains appears to be involved in the catalytic
mechanism of class A b-lactamases, but these mutations, which
extend the substrate profile of the variants, often concomitantly
lower their catalytic efficiencies against the classical, good
substrates of the parent enzymes [96–99]. Three other substi-
tutions, i.e. Leu-35!Gln and Arg-205!Leu in the SHV family
and Ala-42!Val in the TEM family (Tables 3 and 4), observed
further away from the active site, appear to be not negligible, but
of lesser importance [86,91,92], and their real significance remains
to be firmly established.
An attempt was first made to explain the specificity of the
variants on the basis of the three-dimensional structures of
related enzymes (see, e.g., [98,100]). These studies (reviewed in
[57]) drew attention to both the effect of individual mutations
(particularly as positions 164 and 238) and the spectacular
synergistic effect obtained by combining two or three mutations.
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Table 4 Extended-spectrum b-lactamases of the TEM family
The data are compiled from previously published reports [21,86,91,95,188–194], where all
references can be found.
Amino acid at position
39 42 104 164 237 238 240 265 No. of mutations*
TEM-1 Gln Ala Glu Arg Ala Gly Glu Thr —
TEM-2 Lys —
TEM-3 Lys Lys Ser 2
TEM-4 Lys Ser Met 3
TEM-5 Ser Thr Lys 3
TEM-6 Lys His 2
TEM-7 Lys Ser 1
TEM-8 Lys Lys Ser Ser 3
TEM-9 Lys Ser Met 3
TEM-10 Ser Lys 2
TEM-11 Lys His ? 1–2
TEM-12 Ser 1
TEM-13 Lys Met 1
TEM-14 Lys Lys Ser Met 3
TEM-15 Lys Ser 2
TEM-16 Lys Lys His 2
TEM-17 Lys 1
TEM-18 Lys Lys 1
TEM-19 Ser 1
TEM-24 Lys Lys Ser Thr Lys 4
TEM-25 Ser Met 2
TEM-26 Lys Ser 2
TEM-27 His Lys Met 3
TEM-28 His Lys 2
TEM-29 His 1
TEM-42 Lys Val Ser Lys Met 4
TEM-46 Lys Ser Lys 3
* Number of point mutations when compared with the parental type TEM-1/2. Note that
silent mutations can also result in additional differences between the various genes (see e.g.
[163,190,195,196]).
 The same mutations as for the recently reported TEM-43 enzyme [197], which displays
yet an additional Met-182! Thr mutation (see Table 5).
 The same mutations in TEM-21, which bears an additional His-153! Arg mutation
[191].
More recently, the determination of the X-ray structure of the
TEM-1 b-lactamase allowed a more rational examination of the
role of the residues at positions 104, 164, 238 and 240 in the TEM
family [99]. A detailed kinetic study of six TEM mutants obtained
by site-directed mutagenesis was performed and their properties
were analysed using molecular modelling, since no data on the
structures of the variants are presently available. The key roles of
mutations at positions 164 (Arg-164!Ser}His) and 238 (Gly-
238!Ser) could be rationalized on the basis of structural changes
(sections 7.1 and 7.2). Most interestingly, docking the optimized
structures of substrates with bulky oximino moieties on their C-
7 side-chain (cefotaxime and ceftazidime) into the active site of
the wild-type TEM-1 enzyme led to short contacts between the
oxime substituents and the side-chain of Asn-170, which in turn
resulted in a displacement of the carboxylate side-chain of Glu-
166 [99]. Moreover, with ceftazidime, the position of the catalytic
water molecule W1 was also modified, an observation which is
consistent with the even poorer activity of the enzyme against
this substrate. A similar displacement of the catalytically im-
portant water molecule W1 was also deduced from molecular-
modelling analysis of the interaction of the S. albus G b-
lactamase with various b-lactamase-stable antibiotics, including
cefotaxime, ceftazidime and aztreonam [72,83] and, more re-
cently, from a similar study of the mechanism of hydrolysis of
cefepime, a novel oximino cephalosporin, by TEM-1 [101]. These
results confirm yet again, the intimate implication of Glu-166,
Asn-170 and the conserved water molecule W1 in the catalytic
machinery of class A b-lactamases (see also section 9.2).
7.1. The R164 mutants
In most of these enzymes, Arg-164 forms a strong, buried ionic-
bond with the highly conserved Asp-179, which is important for
the conformation and the stability of the X-loop and hence for
the correct positioning of Glu-166 within the active site [102]
(note that three additional stabilizing interactions are found in
the TEM-1 enzyme, namely between Arg-164 and Glu-171,
between Asp-176 and Arg-178 and between Glu-177 and Thr-
180, which all contribute to the locking of the X-loop [49,103]).
In excellent agreement with this, systematic mutagenesis of the
active site X-loop of the TEM-1 b-lactamase [104–106] failed to
produce mutations at positions 164 or 179 (also true for positions
166, 176 and 180), resulting in ampicillin resistance of the host
strain. Accordingly, a significant loss of activity of the Arg-164
!Ser and Arg-164!His mutants derived from TEM-2 (TEM-
7 and TEM-11 respectively) towards the best substrates was
observed (decreased k
cat
values [99]), and this negative factor,
resulting from the perturbation of the X-loop, must actually
reflect on the hydrolytic efficiency of all compounds, including





) of the TEM-7 and TEM-11 mutants against
these two substrates was actually increased by their respective
mutations at position 164, owing to a larger positive effect, i.e.
the disappearance of the short contacts with Asn-170, mainly









addition, removal of the Arg-164 long side-chain allows more
freedom for the oxime carboxylate of ceftazidime, which no
longer disturbs the water molecule W1, hence accounting for the
specifically high activity against ceftazidime (increased k
cat
value
[99]) of the mutants bearing an Arg-164!Ser}His mutation.
Finally, the important feature in the interaction of those TEM
variants harbouring a substitution at position 164 with oximino
b-lactams is not the occurrence of a potential hydrogen-bond
donor, but rather the disappearance of the salt-bridge between
the two highly conserved residues Arg-164 and Asp-179. Re-
cently, Maveyraud et al. [103] proposed that in the Arg-164!
Ser mutant, a significant movement of the X-loop would displace
the large 85–142 region (Figure 3C) of the enzyme, resulting in
better access of cephalosporins with large oximino side-chains
to the active-site cavity, and thus explain the specific en-
hancement of the catalytic efficiency observed for these molecules
relative to other good penicillin and cephalosporin substrates.
Notably, although mutations at position 164 have not been
reported yet in the SHV family (Table 3), a new member (SHV-
8) has been identified which displays a single mutation at position
179 (Asp-179!Asn; [107]). The effects of this new mutation are
most likely analogous to those of the Arg-164!Ser}His substi-
tutions occurring in the TEM family.
7.2. The Gly-238! Ser mutant
Consistent with previous suggestions [88,108,109], and con-
trary to the indirect role suggested for the residue at position 164,
Raquet et al. [99] suggested that the Ser side-chain of the Glu-238
!Ser mutants (TEM-19 and the double mutant TEM-3 were
studied) points into the active-site cavity and is suitably posi-
tioned in order to form a new hydrogen-bond with the oxime
oxygen of cefotaxime. However, this was not found to be
possible with the bulkier substituent of ceftazidime, which would
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create short contacts with the hydroxymethyl group of Ser-238.
To avoid these short contacts, the side-chain of ceftazidime must
be oriented away from the active site, which allows the return of
W1 to its efficient position and hence a better catalytic efficiency.
Therefore, with these Ser-238 mutants, the structural changes in







(increased values, enhanced by the second
mutation Glu-104!Lys in TEM-3) for both cefotaxime and
ceftazidime [99], but this improved catalytic efficiency was
proposed to originate from very different factors, i.e. on the one
hand, a new direct interaction between the enzyme Ser-238 side-
chain and cefotaxime and, on the other hand, a different, more
favourable, positioning of ceftazidime in the active-site cleft.
In contrast, Knox and co-workers [100,110] suggested that the
introduction of a large side-chain (larger than Ala, e.g. the
hydroxymethyl group of Ser) at position 238 would displace the
b-3 strand and result in a slightly expanded active site which
would accommodate cephalosporins with bulky side-chains. This
hypothesis has the advantage of partly accounting for the
observed increase in activity against cefotaxime of in itro mutant
enzymes of the TEM (Gly-238!Ala, [111]) and SHV (Gly-238
!Val [109]) families, which obviously cannot form a new
hydrogen-bond with the oxime moiety of the substrate. However,
it was argued [112] that the dense hydrogen-bond network found
in the particular area of the active site would impede any
movement of the C-terminal edge of the b-3 strand, where
residue 238 lies. Rather, modelling of the Gly-238!Ser sub-
stitution in the three-dimensional structure of TEM-1 [99,112]
suggested some new interactions between Ser-238 and Asn-170,
which might again result in a slight displacement of the Glu-166
side-chain, hence explaining the decreased k
cat
values observed
with the best substrates. Conversely, such subtle conformational
changes of that part of the X-loop could, ‘ in some way’, be
responsible for enhanced catalytic efficiency towards cefotaxime
[112] and, more globally, towards compounds with an oxime
substituent on C-7 (e.g. ceftazidime).
Similar changes, probably also resulting from steric effects
[112], might well be obtained with Ala or Val at position 238,
thus explaining the altered specificity of the Gly-238!Ala and
Gly-238!Val mutants quoted above. Nevertheless, recent
screening for in itro mutants with highly (100-fold) increased
resistance to ceftazidime [113] confirmed that, although several
substitutions at position 238 can increase activity, the best
combination of substitutions in that region includes Ser at
position 238, Lys or Arg at position 240 and a small amino acid
at position 241. One can hypothesize that various side-chains,
including the methyl group of Ala at position 238, induce some
minor structural changes that allow a better positioning of those
substrates bearing large oxime substituents. This positive effect
would more than compensate for the negative effect observed
with the good substrates, i.e. a decrease in activity, caused by
slight perturbations of the X-loop and poor positioning of the
Glu-166 carboxylate side-chain. The decreased stability of the
Gly-238!Ser mutant [114] might indeed reflect an altered
conformation of the active site. Recent experiments [112] sug-
gested that with the Gly-238!Ser mutant of the TEM-1 enzyme,
both the acylation and the deacylation steps might be affected by
the change in the active-site conformation. Interestingly, these
conclusions are again in good agreement with the proposal [50]
of a dual role for Glu-166 in both the acylation and deacylation
steps.
Finally an engineered S. aureus PC1 b-lactamase (Ala-238!
Ser and Ile-239 deleted) displays enhanced activity towards
third-generation cephalosporins [115]. Interestingly, the X-ray
structure of the mutant revealed both an altered disposition of
the b-strand, resulting in an opening of the active-site cavity, and
a significant displacement of Glu-166. Although the S. aureus
mutant is much less efficient than the TEM enzymes (including
TEM-1}2) against cefotaxime and ceftazidime, these observed
structural changes are similar to those discussed here for the
TEM variants bearing a Gly-238!Ser mutation.
7.3. The Glu-104! Lys and Glu-240! Lys mutations
The prevalence of several mutations in the same enzyme (Tables
3 and 4) has been largely documented and, in that respect, several
attempts have been made to unravel the individual contributions
of Lys at positions 104 and 240. In both cases, the ammonium
group of the long Lys side-chain has been suggested to interact
with the carboxylic group on oximino substituents of ceftazidime
and aztreonam [110]. Unfortunately, in the absence of three-
dimensional structures for these proteins, modelling of the
mutants with new Lys side-chains (e.g. TEM-3, TEM-10 and
TEM-18) is made difficult by the large number of possible
conformations of the long alkyl moiety of this residue [99]. The
activity compared with the good substrates of the single Glu-104
!Lys mutant (TEM-18) was found to be unaffected [99], a
behaviour very similar to that of the Glu-104!Lys mutant
studied by Sowek et al. [98]. It was shown that the ammonium
group of the two Lys side-chains can indeed position similarly in
the active site without modifying its structure or inducing short
contacts [99]. This agrees with a similar role for the two
substitutions. Recent work by Petit et al. [116] has suggested that
a lysine at position 104 might alter the precise positioning of
residues 130–132 (SDN loop) which are involved in substrate
binding and catalysis.
Further details about the role of the individual residues
involved in the extended substrate profile of the TEM and SHV
variants can be found in the recent and thorough review by Knox
[110].
8. INHIBITOR-RESISTANT b-LACTAMASES OF THE TEM FAMILY
The ES b-lactamases derived from TEM-1}2 and SHV-1 de-
scribed above remain sensitive to b-lactamase inhibitors such as
clavulanic acid, sulbactam and tazobactam (Figure 1). These
compounds, which have generally little antibiotic activity by
themselves, behave as mechanism-based inactivators of most
class A b-lactamases, and therefore are able to potentiate the
action of classical b-lactamase-sensitive compounds by protecting
them from enzymic hydrolysis [12,79]. These ‘wonder ’ drugs
have beenwidely used against theb-lactamase-producing bacteria
and, for instance, clavulanic acid combined with amoxycillin
(Augmentin) represents a powerful clinical strategy to overcome
the resistance of bacteria harbouring the TEM b-lactamase
variants [117]. However, bacterial susceptibility to such com-
binations of efficient b-lactam antibiotics and potent b-lactamase
inactivators was first reported to be challenged by the over-
production of TEM-1 or SHV-1 b-lactamases [117–121]. More
worrying were later reports of novel TEM-type b-lactamases in
Escherichia coli clinical isolates [122,123], and more recently in
other species of Enterobacteriaceae (K. pneumoniae, [124] ; Pro-
teus mirabilis, [125]), which are resistant to these mechanism-
based inactivators. The inhibitor-resistant TEM b-lactamases
(IRTs) differ from TEM-1}2 by one, two or three amino acids
substitutions at new locations (69, 165, 244, 275 and 276; Table
5), which decrease the affinity for b-lactam substrates and alter
the inhibitory action of suicide substrates such as clavulanic acid
[124–131].
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Table 5 Inhibitor-resistant b-lactamases of the TEM family
Amino acid at position
69 165 244 275 276 References
TEM-1 Met Trp Arg Arg Asn [198]
IRT-1 (TEM-31) Cys [123,124,127,130]
IRT-2 (TEM-30) Ser [123–125,127,130,131]
IRT-3 (TEM-32)* Ile [126,131,199]
IRT-4 (TEM-35) Leu Asp [128,130,131]
IRT-5 (TEM-33) Leu [130,131]
IRT-6 (TEM-34) Val [130,131]
IRT-7 (TEM-36) Val Asp [130,131]
IRT-8 (TEM-37) Ile Asp [131]
IRT-9 (TEM-38) Val Leu [131]
IRT-10 (TEM-39) Leu Arg Asp [131]
IRT-I67 (TEM-40)* Ile [131,199]
TEM-41 Thr [199]
IRT-14 (TEM-45) Leu Gln [200]
* In these two enzymes, the Met-69! Ile substitution has been found either in
combination with an additional mutation at position 182 (Met-69! Ile­Met-182! Thr,
called IRT-3, [126]) or as a single point mutation (Met-69! Ile, [131], called IRT-I67 (TEM-
40) by Stapleton et al. [199]), but it was clearly established that only the mutation at position
69 (Met-69! Ile) was involved in resistance to suicide inhibitors [126,137]. However, the
presence of a Thr at position 182 might facilitate the required structural change at position 69
[110] and was shown to partially compensate for loss in catalytic activity due to the Met-69
! Ile substitution [137]. Note also that a residue (Thr, Ser or Cys) which can form a hydrogen-
bond is found at position 182 in the sequences of most b-lactamases [137].
8.1. Residue 69
A methionine is present at position 69 of the TEM-1 and SHV-
1 enzymes. This residue, which is not conserved in class A b-
lactamases, is situated just next to the nucleophilic serine, but the
two side-chains are not in contact [49]. Residue 69 lies on a short
turn preceding the a-2 helix in the all-a domain and is buried at
the hydrophobic interface between the two domains, with its
side-chain situated behind the b-3 and b-4 strands. It exhibits a
side-chain containing at least one C atom in all class A b-
lactamases, with the sole exception of S. cacaoi Ulg, and it is
found to be in a highly constrained structural environment in all
known structures [47,49,52,132].
Not very long after several reports of laboratory-derived
mutants of the TEM-1 [133,134] and SHV-type OHIO-1 [135] b-
lactamases with a mutation at position 69 (Met-69! Ile, Met-
69!Leu and Met-69!Val) and resistant to clavulanate, sul-
bactam and tazobactam, the same mutations have been found in
numerous inhibitor-resistant TEM b-lactamases from clinical
isolates of E. coli (Table 5).
These observations have been explained by subtle modifi-
cations of the active-site structure [134], and, in particular, a
deformation of the oxyanion hole and a possible change in the
positioning of the guanidinium group of Arg-244, which is
situated on the b-4 strand ([136] ; see section 8.3). More recent
molecular-modelling studies indicated that the substitution of a
Met for an Ile at position 69 (Met-69! Ile) alters the positions
of the essential Glu-166 and Asn-170 side chains, as well as the
position of the catalytic water molecule [137]. This very slight
displacement (0±3 AI for its oxygen) of W1 has been suggested to









values was observed) of the
IRT-3 b-lactamase and for resistance to mechanism-based inacti-
vators.
Table 6 Conserved basic residue at homologous positions in class A
b-lactamases
The data are adapted from previously reported sequence alignments ; all references can be found




Enzymes 220 244 276
Klebsiella pneumoniae LEN-1 ; SHV-1 ; TEM-1 ; Pseudomonas
aeruginosa PSE-3 ; PSE-4 ; Rhodopseudomonas capsulata ; A. R39 ;
Bacillus cereus 569/H type I ; Bacillus cereus 5/B type I ; ROB-1 ;
CARB-4 ; Bacteroides mycoides ; Proteus mirabilis GN 79
Leu Arg Asn
Bacillus cereus 569/H type III ; Bacillus licheniformis ; Streptomyces
cacaoi Ulg ; Staphylococcus aureus PC1 ; Enterobacter faecalis
Leu Arg Asp
Streptomyces badius ; Nocardia lactamdurans Val Arg Asp
Streptomyces cacaoi blaU Leu Arg Ser
Streptomyces cellulosae Thr Arg Thr
Streptomyces albus G Arg Asn Asp
Streptomyces lavendulae ; Streptomyces fradiae Arg Asn Asn
Lysobacter enzymogenes Arg Thr Ser
Per-1/Per-2 Arg Thr Glu
Bacillus uniformis (cblA) Lys Asp Asn
Bacillus fragilis (cepA) Arg Cys Asn
Bacillus vulgatus (cfxA) Arg His Ala
Sme-1/NmcA/IMI-1 Arg Ala Asp
Mycobacterium tuberculosis Arg Ala Glu
Klebsiella oxytoca E23004 ; Citrobacter diversus ; Klebsiella oxytoca
D488 ; Escherichia coli Toho-1 ; Proteus vulgaris ; Serratia fonticola
Ser Thr Lys
Yersinia enterocolitica Thr Thr Arg
Escherichia coli MEN-1 (CTX-M-1) ; CTX-M-2 ; Mycobacterium
fortuitum
Ser Thr Arg
Streptomyces aureofaciens* Thr Ala Asn
* In this enzyme, Arg-218 might correspond to that found at positions 220, 244 or 276 in
all other class A b-lactamases.
8.2. Tryptophan-165
A Trp residue is found in position 165 of the TEM b-lactamases.
It is situated on the X-loop, just next to Glu-166, but with its
side-chain pointing to the surface of the protein. Of the four Trp
residues in the TEM-1 enzyme, only Trp-165 can tolerate amino
acid substitutions which maintain ampicillin resistance in E. coli
[106]. The Trp-165!Arg substitution was found to make little
difference in the catalytic behaviour of the enzyme [138].
A Trp-165!Arg mutation was found in IRT-10, together
with Met-69!Leu and Asn-276!Asp. Although it may be
expected not to play a major role in the resistance to inactivators,
the replacement of Trp-165 by Arg decreases the sensitivity of the
enzyme to inhibition by clavulanic acid, possibly due to subtle
modifications in substrate positioning [138].
8.3. Arginine-244
An arginine residue is present at position 244 in 22 of the 46 class
A sequences considered in this review (Table 6). The a-carbon of
this residue is situated on the b-4 strand of the a}b domain
(Figure 3C), thus rather remote from the active site. However, its
long side-chain points in the direction of the cavity, and the
guanidinium group of Arg-244 is actually positioned close to the
side of the cavity formed by the adjacent b-3 strand containing
the Lys-Thr(Ser)-Gly sequence (Figure 4).
Arg-244 is not conserved in class A enzymes (Table 6), but
when it is absent, a basic residue (Arg or Lys) is found either at
position 220 [139] or at position 276 [140]. A careful comparison








Figure 5 Assumed equivalent positions of the guanidinium groups of arginines 220, 244 and 276
The a-carbon trace and the Arg-244 side-chain are those of the TEM enzyme. The Arg-220 side-chain has been positioned as in the S. albus G b-lactamase crystal structure. The Arg-276 side
chain is oriented in the same direction as that of Asn-276 in the TEM structure.
of the three-dimensional structures of the S. albus G (Arg-220;
Asn-244) and of the B. licheniformis or TEM-1 (Leu-220; Arg-
244) b-lactamases indicated that the guanidinium group of Arg-
220 in the former lies in a position equivalent to that of Arg-244
in the latter ([139] ; Figure 5). Similarly, Arg at position 276, which
is structurally close to position 220 [54], can overlap with those
at positions 220 or 244 ([140] ; Figure 5). Interestingly, data in
Table 6 indicates that a lysine residue can be found in place of an
arginine both at positions 220 and 276. Conversely, no ‘natural ’
enzyme has been identified to date with a Lys-244, but the
artificial Arg-244!Lys mutant of the TEM-1 b-lactamase was
not significantly different from the wild-type enzyme [141], thus
suggesting that a lysine residue could well be found at position
244 in presently non-sequenced enzymes.
Site-directed mutagenesis experiments indicated that an ar-
ginine (or a lysine) at position 220 or 244 is critical for the
catalytic properties of the S. albus G [139] and TEM-1 [134,141]
b-lactamases respectively, and the same is expected to hold true
for Arg-276 in various enzymes [140]. A basic residue at position
220, 244 or 276 might, directly or indirectly, interact with the
negatively charged carboxylate group of b-lactam substrates
[48,53,64,65,134,139,141] and thus contribute to substrate bind-
ing at the ground and}or at the transition state.
Another major feature of Arg-244 is its implication in the
mechanism of b-lactamase inactivation by suicide substrates.
Indeed, in an effort towards the understanding of the details of the
interaction of mechanism-based inactivators with the active-site
serine b-lactamases, Mobashery and co-workers [64,65] reported
that the Arg-244!Ser mutant of the TEM-1 b-lactamase was
resistant to inactivation by clavulanate (both in itro and in io)
and sulbactam. Similar results were also reported by Delaire et
al. [134] who observed that replacement of Arg-244 by most
other amino acids resulted in increased resistance to inactivation
by clavulanate and sulbactam. As suggested for its interaction
with the classical substrates, Arg-244 would be involved in
effective binding of the inhibitor [64,65]. Additionally, together
with the backbone carbonyl group of Val-216, the guanidinium
of Arg-244 would serve as an ‘electrostatic anchor’ for a
structurally conserved water molecule which would play a critical
role in the inactivation mechanism [64]. This water molecule
would be an essential source of proton in the mechanism of b-
lactamase inactivation by both clavulanic acid [64] and carba-
penem antibiotics [142]. Although Arg-244 is also probably
involved in the inactivation chemistry of sulbactam [65], and
possibly tazobactam, this is not as well documented as for
clavulanate or imipenem.
Not surprisingly, among the naturally occurring TEM mutants
recently identified, and which exhibit a decreased sensitivity to
clavulanic acid, sulbactam and tazobactam, some were found
with a mutation at position 244 (Table 5), thus confirming the
alarming findings obtained with the corresponding laboratory
mutants.
Importantly, recent site-directed mutagenesis experiments
[143,144] and the isolation [145] of a new complex mutant of the
TEM-1 enzyme (referred to asCMT-1 or TEM-50) both indicated
that the combination ofmutations resulting in inhibitor resistance
(e.g. Met-69!Leu and Asn-276!Asp in TEM-50) and in ES
activity (e.g. Glu-104!Lys and Gly-238!Ser in TEM-50) are
largely incompatible. This finding is somewhat reassuring (per-
haps temporarily) as it suggests that TEM variants conferring
both activity against ES cephalosporins and resistance to b-
lactam inactivators cannot be obtained by mere addition of
mutations characteristic of each class of mutants (Tables 4 and
5). Thus it appears that it would be more efficient for an E. coli
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strain to produce two different TEM mutants (an ES and an IRT
mutant) simultaneously rather than to produce a single mutant
combining mutations of both types [145]. However, this bacterial
strategy would be efficient against third-generation cephalo-
sporins and Augmentin (clavulanate­amoxycillin) taken in-
dividually, but not against a mixture of a third-generation
cephalosporin and clavulanate.
Interestingly, an inhibitor-resistant b-lactamase (SHV-10) de-
rived from an SHV-5 variant (SHV-9, Table 3) was recently
reported [146]. In SHV-10, Ser-130 is replaced by Gly. In this
case, it was observed that the enzyme partially retains its ability
to hydrolyse penicillins, but its activity against cephalosporins,
including cefotaxime and ceftazidime, is drastically reduced.
8.4. Residues 275 and 276
An arginine and an asparagine residue are present in the TEM
enzymes at positions 275 and 276 respectively. To date, mutations
at these two positions have never been observed alone (Table 5),
and hence their role in resistance to suicide substrates seems
questionable [130,131]. However, crystallographic data indicate
that Asn-276, which is situated at the C-terminal extremity of the
enzyme in the a}b domain (Figure 3C), restricts the mobility of
the Arg-244 side-chain and contributes to maintaining active-site
integrity [49,134]. Substitutions at this position might thus be
expected to have an effect on the mechanism of resistance to
suicide substrates similar to that of mutations at residue 244
[128,131]. Conversely, the role of mutations at position 275 is less
clear.
Kinetic, electrospray MS and molecular-modelling studies of
the Asn-276!Asp mutant of TEM-1 [147] indicated that the





values reduced to 10–50% of those of the wild-type)
and confirmed the significance of an aspartic acid residue at
position 276 in the resistance to inactivation by clavulanic acid.
This seems to result from both a substantial loss of affinity for
the inactivator (23-fold increase in K
i
) and an increase of the




), which represents the
ratio of the number of productive turnovers to those leading to
irreversible enzyme inactivation. The altered electrostatic inter-
action between residues at positions 244 and 276 and the
possible displacement of the water molecule involved in the
inactivation process (hydrogen-bonded to Val-216 and Arg-244,
see above) would be responsible for the new catalytic properties
of the mutant [147].
The Asn-276!Gly mutant of the OHIO-1 b-lactamase [148]
confirms the contribution of a mutation at position 276 in the
resistance to clavulanic acid. However, the affinities for two
penam sulphones (sulbactam and tazobactam) were found to
increase, a result which contrasts with the data obtained with the
Arg-244!Ser mutant of the TEM-1 b-lactamase [65].
To close this section on IRTs, it is interesting to note that
changes at residues 69, 244 and 276 all alter the binding of the
substrate to the enzyme. Hence, it is probably not surprising that
the natural variants containing changes at these positions (Table
5) are less sensitive to small b-lactams, such as clavulanic acid
and sulbactam, which are devoid of an acyl side-chain (Figure 1;
tazobactam, which bears a bulky triazole group on C-2, also lacks
a substituent onC-6) andwould therefore rely primarily on attrac-
tive interactions with the oxyanion hole and Arg-244 [110]. In
agreement with that proposal, it was observed [139] with the Arg-
220!Leu mutant of the S. albus G b-lactamase (where
Arg-220 corresponds to Arg-244 in the TEM b-lactamase, see
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9. MORE EXTENDED-SPECTRUM b-LACTAMASES
Although the number of newly identified plasmidic b-lactamases
of the TEM and SHV type (not considering the variants with
decreased susceptibilities to suicide substrates) has decreased in
the past few years [86], several new bla genes, coding for ES b-
lactamases belonging to the four structural classes A, B, C and
D, have emerged [23,149,150]. The bla genes for the new class A
enzymes, which are located either on a chromosome or on a
plasmid (or both in the case of PER-1) in Gram-negative bacteria,
are too distant from the TEM- or SHV-type genes to represent
direct mutational derivatives. Rather, these genes truly cor-
respond to additions to the ‘pool of resistance genes’, some of
which are expected to disseminate within the microbial popula-
tions by a variety of gene-transfer mechanisms [10]. These bla
genes thus constitute ‘reservoirs ’ of new b-lactamases with so far
unknown variability, which embody a new generation of ES b-
lactamases beyond the TEM and SHV variants [151].
Most of the recently reported enzymes are found in Table 7.
Their sequences increase the already large number of reported
sequences of class A b-lactamases. Table 1 indicates that addition
of these new sequences dramatically reduces the number of
residues that are strictly conserved in all the class A enzymes. In
Table 7, which was adapted from previously published sequence
alignments (for references, see Table 1), we focused the com-
Table 7 Class A extended-spectrum b-lactamases not belonging to the
TEM and SHV families
The data are adapted from previously reported sequence alignments (references are included).
Amino acid at position
b-Lactamase 104 164 165 237 238 240 References
ES TEM variants Lys Ser/His Trp Thr Ser Lys [21]
P. vulgaris Ala Arg Lys Ser Gly Asp* [140,158]
K. oxytoca Val Arg Thr Ala Gly Asp* [140,158,164]
L. enzymogenes Ser Arg Asn Ser Gly ?* [158,201]
MEN-1/CTX-M-2 Asn Arg Thr Ser Gly Asp* [140,158,161,176]
E. coli Toho-1 Asn Arg Thr Ser Gly Asp* [140]
S. fonticola Asn Arg Thr Ser Gly Asp* [165]
C. diversus Asn Arg Lys Ala Gly Asp* [140,158]
Y. enterocolitica Ser Arg Trp Ser Gly Asp* [140,158,161,164]
B. uniformis (cblA) Thr* Glu Thr Ser Ser Gly* [151,160]
B. fragilis (cepA) Thr* His Thr Thr Gly Gly* [151,160]
B. vulgatus (cfxA) Thr* Tyr Thr Ser Gly Gly* [160,161]
Per-1/Per-2s Thr* Ala Asn Thr Ser* Gly* [151,161]
M. fortuitum Pro Arg Trp Ser Gly Asp* [140,202]
NmcA/IMI-1 Phe Arg Trp Ser Gly* Ala* [169,171]
Sme-1 Tyr Arg Trp Ser Gly* Ala* [169,171]
* Due to insertions or deletions in that region of the sequence, the residue corresponding
to this particular position in the TEM sequences is uncertain.
 Residue (Trp) at position 165 in the TEM family is not involved in extended-spectrum
properties (see the text).
 The catalytic properties of these enzymes are unclear. Nevertheless, L. enzymogenes was
observed to significantly hydrolyse cefotaxime [203], and cfxA was reported to be responsible
for cefoxitin resistance in Bacteroides species [25]. Conversely, Y. enterocolitica is apparently
not an ES b-lactamase, as no hydrolysis could be detected after 2 h of incubation with either
cefotaxime or cefoxitin [166].
 MEN-1, also called CTX-M-1, is 84% identical with CTX-M-2 [176].
s 86±4% isology [151].
 97% identity [171].
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parison on the 23 strictly conserved residues observed by Ambler
et al. [58] in their alignment of 20 class A b-lactamases. Table 1
clearly shows that, when the new sequences are included in the
alignment (46 of the class A sequences reported to date have been
considered here), the number of residues that are strictly con-
served decreases to nine, the Bacteroides (cblA, cepA and cfxA)
and the Per-1}Per-2 enzymes largely contributing to this in-
creased diversity in the sequences. Additionally, important active-
site residues at positions 132, 234 and 235 can also be regarded
as highly conserved. Indeed, only conservative mutations have
been identified at these positions, although a Gly is found at
position 132 in the sequence of the M. tuberculosis enzyme (Table
1). A similar situation prevails for several residues remote from
the active site, but probably playing an important structural role
(e.g. residues at position 66 and 199).
Not surprisingly, the essential residues for catalysis [Ser-70,
Lys-73, Ser-130, Glu-166 and Lys(Arg)-234; Figure 4] are strictly
conserved in all class A b-lactamases. Furthermore, residues at
positions 132 (Asn in 44 out of the 46 sequences analysed) and
235 (Ser or Thr) have been shown to be important for enzyme
activity, especially towards cephalosporins [61,152–155]. Five
residues (Gly-45, Pro-107, Asp-131, Ala-134 and Gly-236) are
left, which are most probably conserved for structural reasons.
Gly-45 is situated on the b-1 strand in the first hinge-region
connecting the two structural domains, i.e. at the interface
between these two domains, where no residue other than Gly
could be sterically accommodated [49]. Pro-107 forms part of a
distorted type I turn [49], and probably makes a critical con-
tribution to the conformation of the polypeptide chain in this
region [106]. Asp-131 is located on the short SDN loop between
helices a-4 and a-5, which is nearly invariant in class A b-
lactamases. Its side-chain is buried in the protein core and is
involved in several hydrogen-bonds, probably ensuring the
correct positioning of the SDN loop [49,153]. Ala-134 is situated
in the hydrophobic core of the a-domain, whereas the strict
conservation of Gly-236 in the superfamily of active-site serine
penicillin-recognizing enzymes [42] can be attributed to purely
steric factors [57].
Interestingly, in their systematic search (by random muta-
genesis) for mutants of the TEM-1 b-lactamase conferring wild-
type level of ampicillin resistance to E. coli, Huang et al. [106]
observed that none of these 12 residues tolerated amino acid
substitutions, with the sole exception of the residue at position
45, for which a mutant exhibiting an alanine residue was selected.
As indicated by this experiment, and although the five residues
which do not participate in the catalytic process were found to be
strictly conserved in the 46 sequences analysed here (Table 1), it
cannot be ruled out that new enzymes with mutations at these
apparently important positions will emerge in the future. Indeed,
several residues, which not long ago were regarded as being
invariant among classA enzymes for important structural reasons
(e.g. Glu-37, Gly-144, Arg-164 and Asp-233; Table 1), have been
found to be non-conservatively substituted in some of the recently
reported ES b-lactamases not belonging to the TEM and SHV
families (Table 1). Remarkably, we note that two SHV derivatives
(SHV-9 [156] and SHV-10 [146]) with a deletion at position 45
(Gly-45) have been reported recently.
Several attempts have been made to correlate the extended
catalytic properties of these enzymes to their structural charac-
teristics (see e.g. [132,157–159]). In Table 7, we compare the
residues found to be critical for ES properties in the TEM
variants (see section 7) with those occurring at corresponding
positions in the sequences of the unrelated ES enzymes discussed
here. It should be stressed that this comparison must be con-
sidered cautiously. Indeed, in the absence of three-dimensional
structures for these b-lactamases (except for NmcA, see
section 9.2), it cannot be ruled out that residues found at
equivalent, or supposed equivalent, positions in the various
sequences aligned according to Ambler et al. [58], might actually
occupy substantially different positions in their respective active
sites. Moreover, proper alignment of these numerous sequences
is made difficult by the presence of insertions or deletions in
several enzymes. For instance, the three enzymes from Bac-
teroides species (cb1A, cepA and cfxA) and the PER-1}2 enzymes
possess additional amino acid residues at several positions
compared with other class A b-lactamases, in particular down-
stream from the Lys-Thr-Gly triad, where 4–5 additional residues
are found [160,161]. Thus the conclusions inferred from studies
of the TEM variants, which largely rely on the X-ray structure of
the wild type enzyme (TEM-1), do not necessarily apply to
enzymes which generally show less than 50% sequence identity
with TEM-1.
9.1. Hydroxylated residues at positions 165, 237 and 238
The most striking feature of most of the ES enzymes in Table 7
is the occurrence of a hydroxylated residue (Ser or Thr) at
position 237. In class A b-lactamases, the side-chain (if any) of
residue 237 (generally Ala or Gly) is on the outer, exposed side
of the b-3 strand that forms the right edge of the binding site
(Figure 3C). This residue is, however, part of the hydrogen-bond
network that stabilizes binding of the substrate in the active site.
Indeed, the main-chain NH group of residue 237 interacts with
the oxygen of the b-lactam carbonyl, thus contributing to the
formation of the oxyanion hole, and a second hydrogen-bond is
formed between the main-chain carbonyl group of residue 237
and the amide NH group of the substrate side-chain [46,48,50].
A clear indication of the relevance of Thr at position 237 in the
TEM variants came recently from a crystallographic mapping of
complexes of cephalothin and cefotaxime with the structurally
homologous S. R61 DD-peptidase [162]. In this enzyme, cefo-
taxime, with its branched rigid C-7 acyl side-chain, was found to
be unable to form the hydrogen-bond with the backbone CO
group at position 237 (301 in the DD-peptidase), which is
normally observed with cephalothin. Instead, the ‘ tilted’ cefo-
taxime binds to the side-chain OH group of Thr, which occupies
this position in the DD-peptidase. By analogy, the substitution
of Ala-237 by Thr in TEM-5 and TEM-24 was proposed to
enhance the binding of b-lactams with oximino substituents
and}or to help align the acyl-enzyme intermediate for attack by
the hydrolytic water molecule [110,162]. Similarly, the P. ulgaris
b-lactamase, which contains a Ser residue at position 237, showed
significantly decreased activity towards oximino cephalosporins
when Ser-237 was replaced by Ala using site-directed mutagenesis
([159] ; M. Datz and J.-M. Fre' re, unpublished work; Table 8).
Conversely, the mutation scarcely affected the activity towards
the other substrates tested (including aztreonam, Table 8), a
slight increase in catalytic efficiency being generally observed,
evenwith first generation cephalosporins (cephaloridine, cephalo-
thin and cefazolin). Further comparison of the kinetic parameter
values of the various enzymes in Table 8, some of which are
devoid of Ser (or any other hydrogen-bond donor) at position
237, supports the idea [158,163–165] that Ser-237 (or Thr-237)
contributes to the ability of ES b-lactamases (e.g. P. ulgaris,
MEN-1, Toho-1, S. fonticola and Per-1) to hydrolyse oximino
b-lactams (although this is less clear for aztreonam). However, it
also suggests that some other residues are responsible for the
high catalytic activity of these enzymes towards these particular
compounds and cephalosporins in general. In that respect, it is
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Table 8 Comparison of the kcat/Km values (mM−
1[s−1) for the hydrolysis of some characteristic b-lactams by various class A ES b-lactamases
The values in parentheses are relative to those for benzylpenicillin arbitrarily fixed at 100. For Per-1, only relative values were reported. The data are from Reynaud et al. [157] (K. oxytoca D488),
Barthe! le!my et al. [164] (K. oxytoca D488 and MEN-1), M. Datz and J.-M. Fre' re (unpublished work) (Proteus vulgaris CumA ), Ishii et al. [140] (Toho-1), Pe! duzzi et al. [165] (S. fonticola), Nordmann


















Benzylpenicillin 8300 (100) 33000 (100) 700 (100) 640 (100) 17000 (100) 11000 (100) 33000 (100) (100)
Ampicillin 5400 (65) 23000 (68) 600 (86) 450 (71) 8700 (50) 5700 (51) ND ND
Cephaloridine 1250 (15) 5800 (17) 1500 (210) 1100 (170) ND 1500 (13) 14000 (43) (56)
Cephalothin 1300 (16) 5000 (15) 3200 (460) 1700 (270) 21300 (120) 630 (5) 41000 (120) (170)
Cefazolin 8300 (100) ND 3200 (460) 2700 (430) ND ND ND ND
Cefuroxime 770 (9) 650 (1±9) 360 (51) 1300 (200) 2000 (12) ND 27000 (81) (93)
Cefotaxime ND 110 (0±3) 120 (17) 470 (74) 2500 (15) 1900 (17) 11000 (34) (150)
Ceftazidime ND (—) 1±9 (0±3) 10 (1±6) 20 (0±1) 430 (4) 60 (0±2) (42)
Aztreonam (—) 100 (0±3) 150 (21) 160 (25) ND 91 (0±9) 930 (3) (0±1)
interesting to note that the Ala-237!Thr mutation has been
found only in two ES b-lactamases of the TEM family (TEM-5
and TEM-24), and, in both cases, it was observed to occur in
combination with at least two other mutations important for
extended activity (Table 4). It is also noteworthy that no
hydrolysis of third-generation cephalosporins could be observed
with the b-lactamase of Y. enterocolitica [166], which harbours a
Ser residue at position 237 and displays a high level of similarity
to the K. oxytoca (" 70% identity) and MEN-1 (C 60%
identity) enzymes [164]. This observation clearly indicates that a
Ser residue at position 237 is not the only requirement for
hydrolytic activity against oximino cephalosporins and, again, it
draws attention to the subtle differences that exist between the
active sites of the various class A enzymes.
Table 8 indicates that C. diersus (Ala-237), K. oxytoca (Ala-
237) and the Ser-237!Ala mutant of P. ulgaris are very










" 10& M−"[s−") towards second- (cefuroxime) and even
third-generation (cefotaxime) cephalosporins. Interestingly, the
activity of the K. oxytoca enzyme towards cefotaxime has been
attributed to Thr-165 [157]. It has been suggested that the
hydroxyl group of that residue might interact with the oxime
substituant of cefotaxime through the formation of a new
hydrogen-bond. Remarkably, it can be seen in Table 7 that a
potential hydrogen-bond donor (Thr, Asn or Lys) is found at
position 165 in most ES b-lactamases, whereas a hydrophobic
residue (Trp, Phe, Tyr, Ile, Val or Leu) is found in most other
class A enzymes.
Finally, for the Per-1}2 b-lactamases and the cfxA gene
product, the strategy is particularly reminiscent of that in the
TEM family [99]. Indeed, next to a hydroxylated residue (Ser or
Thr) at position 237, residue 238 is a serine in Per-1}2 (also in
cb1A, whose catalytic properties remain unknown) and residues
164 (Tyr or Ala) and 179 (Asn) are both neutral, thus
precluding the possibility of salt-bridge formation between them.
9.2. Carbapenem-hydrolysing b-lactamases
All the ES b-lactamases described so far, belonging or not to
the TEM and SHV families, have been found to hydrolyse













+] at very slow rates. Accordingly, most
pathogenic bacterial strains producing these enzymes, and hence
resistant to ES cephalosporins, are susceptible to imipenem. The
high resistance of imipenem and related carbapenem antibiotics
(e.g. meropenem) to most b-lactamases, combined with their
broad antibacterial activity, make these compounds very efficient
antibiotics, often used in the last resort for patients in intensive-
care units. However, b-lactamase-mediated resistance to carba-
penems has recently been reported. These carbapenem-hydro-
lysing enzymes (‘carbapenemases’) belong to two major groups.
The first group corresponds to class B metallo-b-lactamases
[32,33,167], which require a Zn#+ ion for their activity, whereas
the second one consists (so far) of three class A b-lactamases
from Enterobacter cloacae (NmcA and IMI-1) and Serratia
marcescens (Sme-1), sharing about 70% sequence [168–171].
Kinetic studies performed with the class A carbapenemases
(Table 2) showed that they are very broad-spectrum b-lactamases,
hydrolysing efficiently both classical penams and cephems, but
also a wide range of b-lactam substrates usually considered as
resistant to class A enzymes.
Molecular modelling analysis performed with TEM-1 provided
some clues to the structural determinants of the high stability of
imipenem towards class A b-lactamases [132,172]. These studies
suggested that the relatively low acylation rate (C 10$ M−"[s−")
observed with imipenem can be explained by a significantly
decreased interaction between the b-lactam carbonyl and the
oxyanion hole [132]. Energy-minimized structures for the two
acyl-enzyme intermediates (D"- and D#-tautomers) indicated that
the hydroxyl group of the C-6-a hydroxyethyl moiety of imi-
penem makes a strong hydrogen-bond to the side-chain of Asn-
132, hence orienting the C-6-a side-chain in a position that
displaces the hydrolytic water molecule from its optimal position
[172]. This structural factor was proposed to be the basis for the
slow turnover (k
cat
' 1 s−") of imipenem by the TEM-1 enzyme
[172] and was judiciously exploited for the design of a new
mechanism-based inactivator, 6-a-(hydroxymethyl)penicillanate,
of the same enzyme [173]. This molecule, which is a simple
structural variant of penicillanic acid (i.e. a relatively poor
substrate of TEM-1 and various class A b-lactamases ; Table 2),
harbours a C-6-a hydroxymethyl side-chain resembling that of
imipenem and it behaves, in fact, as a potent inactivator of the
TEM-1 b-lactamase, with turnover values very similar to those
measured for imipenem (k
cat
E 0±03–0±04 s−" and K
m
E 25 lM;
[173]). Interestingly, energy-minimized structures of both the
Henri–Michaelis and the acyl-enzyme intermediates for 6-a-
(hydroxymethyl)penicillanate in the active site of the TEM-1 b-
lactamase indicated a significant displacement of the catalytic
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water molecule [173], which was later confirmed by the crystal
structure of this acyl-enzyme [103]. As with imipenem, this is
likely to explain the retarded rate of hydrolysis of the acyl-
enzyme complex [173], but it might also account for the decreased
rate of acylation when compared with penicillanic acid (Table 2).
A similar displacement of the catalytic water molecule (W1) in
the Henri–Michaelis complex was proposed to be responsible for
the slow rate of acylation observed with imipenem and the S.
albus G b-lactamase ([83] ; Table 2). Again, this effect on both the
acylation and deacylation rates is similar to that observed with
cefoxitin and moxalactam (section 7) and with other b-lactamase-
stable antibiotics (see above). Consistent with several studies of
Glu-166 mutants (section 6), the effect observed here with
imipenem and 6-a-(hydroxymethyl)penicillanate seems more
critical for deacylation than for acylation, which can still proceed
at significant rates (10#–10% M−"[s−" ; Table 2).
In the class A carbapenemases, the presence of a disulphide
bridge between Cys-69 and Cys-238, which creates a new covalent
bondbetween the two domains, significantly modifies the position
of the b-3 strand and, consequently, the active-site geometry
[55,132]. Compared with TEM-1, the distance between the C-a
positions of residues 69 and 238 is reduced by 1±3 AI in NmcA
[55]. Docking of imipenem in the three-dimensional models of
NmcA and Sme-1 [132] suggested that this unique structural
feature might be a major determinant in the characteristic
substrate profiles of these b-lactamases. Indeed, in the modelled
structures, the carbonyl group of imipenem is found to be closer
to the backbone NHs of residues 237 and 70 than in TEM-1,
which significantly improves the interaction with the oxyanion
hole.
Another major characteristic of these enzymes is the altered
position of Asn-132 [due to an insertion after residue 140 (Arg-
140a)], which is shifted away from the b-3 strand by 1±2 AI when
compared with TEM-1 [55]. This residue has been proposed,
both on the basis of crystallographic data [46,53] and of site-
directed mutagenesis and molecular-modelling experiments
[62,152,153,174], to act as a hydrogen-bond donor to the carbonyl
group of the antibiotic side-chain, and to be involved both in the
binding of the substrate and in the catalytic mechanism. Mol-
ecular modelling and kinetic analysis indicated that, in NmcA,
there is no interaction between the oxygen atom of the 6-b-
acylamido group of benzylpenicillin and Asn-132, which would





this substrate by NmcA when compared with TEM-1 (P. Sware!n,
J.-M. Fre' re and J. P. Samama, unpublished work, Table 2). But
most importantly, imipenem was proposed to be better accom-
modated in the enzyme active site, where its more mobile 6-a-
hydroxyethyl substituent, which is at non-binding distance from
Asn-132 (P. Sware!n, J.-M. Fre' re and J. P. Samama, unpublished
work), probably allows proper positioning of the catalytic water
molecule for efficient catalysis. Similarly, NmcA exhibits a fairly
good catalytic efficiency towards 6-a-(hydroxymethyl)penicil-




value about 100-fold higher than that
measured with TEM-1 (Table 2).
In addition to their high carbapenemase activity (k
cat
E
10–10$ s−" for imipenem and meropenem, which is 10$–10&-fold
higher than for other class A b-lactamases ([132,171,175] ; Table
2), another striking feature of NmcA, Sme-1 and IMI-1 is their
ability to hydrolyse compounds bearing a methoxy side-chain on
the a-face of the b-lactam ring (e.g. cefoxitin and moxalactam,
Table 2). As mentioned above (section 7), kinetic and modelling
studies performed with various class A enzymes [72] suggested





! 0±01 s−") rates measured with these compounds are due to
a major displacement of the catalytic water molecule, caused by
the a-methoxy group of the substrate. Molecular modelling with
imipenem and cefoxitin indicated that the 6-a-hydroxyethyl
substituent of imipenem and the 7-a-methoxy group of cefoxitin
adopt similar positions in the active site of NmcA [175], which
could explain the hydrolytic activity of this enzyme on (oxa)-
cephamycins. Table 2 indicates that these enzymes also inactivate
third-generation antibiotics, with a remarkably high efficiency
for aztreonam. We note that the three class A carbapenemases
exhibit a hydroxylated residue at position 237 (Table 7), as found
in most ES b-lactamases (see above).
Finally, on the basis of a sequence alignment [167], a few
additional positions were identified which might contribute to
the carbapenemase activity of these three enzymes, namely 104,
105, 207 and 244. In particular, the absence of arginine at
position 244, which would serve as an ‘electrostatic anchor’ for
a water molecule involved in the inactivation mechanism by
imipenem (section 8.3.), was suggested to be an important factor
[167]. However, Arg-220 in the three class A carbapenemases is
likely to play the same role as proposed for Arg-244 in TEM-1
(see section 8.3 and Table 6).
10. CONCLUSIONS
The tertiary structures of class A b-lactamases which have been
determined to date exhibit a high degree of similarity, which
contrasts with the diversity of the primary structures and the
spectacular variations of the specificity profiles. Since the latter
can also be profoundly modified by a limited number of
mutations, bacteria producing adequate enzymes are easily
selected by the intensive utilization of any given antibiotic.
Future research directions should try to counter the genetic
fluidity of bacteria, which is the cornerstone of their adaptability.
Since one can expect that new b-lactamases will emerge in answer
to the introduction of new b-lactams, it would probably be
interesting to try to synthesize non-b-lactam inhibitors or inactiv-
ators of the DD-transpeptidases, which remain choice targets
for antibacterial drugs. Similarly, non-b-lactam inactivators of
b-lactamases, which would completely escape hydrolysis, might
be quite useful in combined chemotherapies.
Note added in proof (received 20 January 1998)
Recently, active eﬄux pumps have also been implicated in b-
lactam resistance, most markedly in Pseudomonas aeruginosa
[206].
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